PMID- 29105738
OWN - NLM
STAT- MEDLINE
DCOM- 20171226
LR  - 20190221
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 124
IP  - 1
DP  - 2018 Jan 1
TI  - Five-year relative survival for human papillomavirus-associated cancer sites.
PG  - 203-211
LID - 10.1002/cncr.30947 [doi]
AB  - BACKGROUND: Human papillomavirus (HPV) vaccines can potentially prevent greater
      than 90% of cervical and anal cancers as well as a substantial proportion of
      vulvar, vaginal, penile, and oropharyngeal cancers caused by certain HPV types.
      Because more than 38,000 HPV-associated cancers are diagnosed annually in the
      United States, current studies are needed to understand how relative survival
      varies for each of these cancers by certain demographic characteristics, such as 
      race and age. METHODS: The authors examined high-quality data from 27
      population-based cancer registries covering approximately 59% of the US
      population. The analyses were limited to invasive cancers that were diagnosed
      during 2001 through 2011 and followed through 2011 and met specified histologic
      criteria for HPV-associated cancers. Five-year relative survival was calculated
      from diagnosis until death for these cancers by age, race, and sex. RESULTS: The 
      5-year age-standardized relative survival rate was 64.2% for cervical carcinomas,
      52.8% for vaginal squamous cell carcinomas (SCCs), 66% for vulvar SCCs, 47.4% for
      penile SCCs, 65.9% for anal SCCs, 56.2% for rectal SCCs, and 51.2% for
      oropharyngeal SCCs. Five-year relative survival was consistently higher among
      white patients compared with black patients for all HPV-associated cancers across
      all age groups; the greatest differences by race were observed for oropharyngeal 
      SCCs among those aged <60 years and for penile SCCs among those ages 40 to 49
      years compared with other age groups. CONCLUSIONS: There are large disparities in
      relative survival among patients with HPV-associated cancers by sex, race, and
      age. HPV vaccination and improved access to screening (of cancers for which
      screening tests are available) and treatment, especially among groups that
      experience higher incidence and lower survival, may reduce disparities in
      survival from HPV-associated cancers. Cancer 2018;124:203-211. Published 2017.
      This article is a U.S. Government work and is in the public domain in the USA.
CI  - (c) 2017 American Cancer Society.
FAU - Razzaghi, Hilda
AU  - Razzaghi H
AUID- ORCID: http://orcid.org/0000-0002-8053-9748
AD  - National Center for Chronic Disease Prevention and Health Promotion, Centers for 
      Disease Control and Prevention, Atlanta, Georgia.
AD  - Epidemic Intelligence Service Program, Centers for Disease Control and
      Prevention, Atlanta, Georgia.
FAU - Saraiya, Mona
AU  - Saraiya M
AD  - National Center for Chronic Disease Prevention and Health Promotion, Centers for 
      Disease Control and Prevention, Atlanta, Georgia.
FAU - Thompson, Trevor D
AU  - Thompson TD
AD  - National Center for Chronic Disease Prevention and Health Promotion, Centers for 
      Disease Control and Prevention, Atlanta, Georgia.
FAU - Henley, S Jane
AU  - Henley SJ
AD  - National Center for Chronic Disease Prevention and Health Promotion, Centers for 
      Disease Control and Prevention, Atlanta, Georgia.
FAU - Viens, Laura
AU  - Viens L
AD  - National Center for Chronic Disease Prevention and Health Promotion, Centers for 
      Disease Control and Prevention, Atlanta, Georgia.
FAU - Wilson, Reda
AU  - Wilson R
AUID- ORCID: http://orcid.org/0000-0002-3252-9625
AD  - National Center for Chronic Disease Prevention and Health Promotion, Centers for 
      Disease Control and Prevention, Atlanta, Georgia.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
PT  - Journal Article
DEP - 20171106
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - AIM
SB  - IM
CIN - Cancer. 2018 Jan 1;124(1):18-20. PMID: 29105739
MH  - Adult
MH  - African Americans
MH  - Age Factors
MH  - Anus Neoplasms/*mortality/virology
MH  - Carcinoma, Squamous Cell/*mortality/virology
MH  - Databases, Factual
MH  - European Continental Ancestry Group
MH  - Female
MH  - Head and Neck Neoplasms/mortality/virology
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Oropharyngeal Neoplasms/*mortality/virology
MH  - Papillomaviridae
MH  - Papillomavirus Infections/*epidemiology/virology
MH  - Penile Neoplasms/*mortality/virology
MH  - Rectal Neoplasms/mortality/virology
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Survival Rate
MH  - United States
MH  - Uterine Cervical Neoplasms/*mortality/virology
MH  - Vaginal Neoplasms/*mortality/virology
MH  - Vulvar Neoplasms/*mortality/virology
PMC - PMC5793215
MID - NIHMS937480
OTO - NOTNLM
OT  - HPV-associated cancer
OT  - human papillomavirus (HPV) cancer
OT  - relative survival
EDAT- 2017/11/07 06:00
MHDA- 2017/12/27 06:00
CRDT- 2017/11/07 06:00
PHST- 2017/01/11 00:00 [received]
PHST- 2017/04/21 00:00 [revised]
PHST- 2017/04/28 00:00 [accepted]
PHST- 2017/11/07 06:00 [pubmed]
PHST- 2017/12/27 06:00 [medline]
PHST- 2017/11/07 06:00 [entrez]
AID - 10.1002/cncr.30947 [doi]
PST - ppublish
SO  - Cancer. 2018 Jan 1;124(1):203-211. doi: 10.1002/cncr.30947. Epub 2017 Nov 6.